Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.67 |
| ▸ | LPL | P06858 | 12/20 | 0.67 |
| ▸ | F11 | P03951 | 2/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006068 | 0.89 | LIPG (0.81) | LIPGLPLF11ESR2F2 | |
| SCHEMBL2020310 | 0.84 | LPL (0.51) | LIPGLPLF11CA1CA2 | |
| SCHEMBL321437 | 0.83 | LPL (0.53) | LIPGLPLF11ESR2CA1 | |
| SCHEMBL15025955 | 0.82 | LIPG (0.86) | LIPGLPLF11ESR2F2 | |
| SCHEMBL13974429 | 0.82 | LPL (0.49) | LIPGLPLF11ESR2 | |
| SCHEMBL19729193 | 0.81 | LIPG (0.69) | LIPGLPLF11ESR2F2 | |
| SCHEMBL12215734 | 0.80 | LIPG (1.00) | LIPGLPLF11ESR2F2 | |
| SCHEMBL133316 | 0.80 | LIPG (0.87) | LIPGLPLF11ESR2F2 | |
| SCHEMBL31427016 | 0.80 | LIPG (0.73) | LIPGLPLF11ESR2F2 | |
| SCHEMBL1372253 | 0.80 | LIPG (0.67) | LIPGLPLF11ESR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| EP-2044068-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | Merck & Co., Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010964-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | LIPG 2301/4885LPL 2438/4885F11 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.